Merdin, A. Et Al. 2020. Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor. Journal of Oncology Pharmacy Practice , vol.26, no.4 , 929-932.

Merdin, A., Çakar, M. K., Dal, M. S., Mert, D., Yıldız, J., Başçı, S., ... Bakırtaş, M.(2020). Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor. Journal of Oncology Pharmacy Practice , vol.26, no.4, 929-932.

Merdin, Alparslan Et Al. "Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor," Journal of Oncology Pharmacy Practice , vol.26, no.4, 929-932, 2020

Merdin, Alparslan Et Al. "Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor." Journal of Oncology Pharmacy Practice , vol.26, no.4, pp.929-932, 2020

Merdin, A. Et Al. (2020) . "Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor." Journal of Oncology Pharmacy Practice , vol.26, no.4, pp.929-932.

@article{article, author={Alparslan Merdin Et Al. }, title={Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor}, journal={Journal of Oncology Pharmacy Practice}, year=2020, pages={929-932} }